Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection

doi:10.4254/wjh.v9.i4.217

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7545)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

304

WORD

290

HTML

2348

Figures (1-1)

222

Tables (1-2)

206

Sum=3370

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

433

Download

765

Sum=1198

Publishing Process of This Article

Item

Count

Browse

983

Download

1994

Sum=2977

Feb 8, 2017 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Hepatol. Feb 8, 2017; 9(4): 217-223
Published online Feb 8, 2017. doi: 10.4254/wjh.v9.i4.217

Open in New Tab Full Size Figure Download Figure

Figure 1 Overall study design. Group A refers to treatment naïve participants while Group B refers to treatment experienced participants. PEG/WBR treatment is pegylated-interferon alfa 2b (PEG-IFN) and weight-based ribavirin (WBR). ¹Cirrhotic participants received 44 wk of triple therapy. SVR12: HCV RNA < LLOQ, target not detected at 12 wk post treatment discontinuation; BOC: Boceprevir; SVR: Sustained viral response; HCV: Hepatitis C virus; LLOQ: Lower limit of quantification.

Citation: Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, the ACTG 5294 BIRTH Study Team. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol 2017; 9(4): 217-223
URL: https://www.wjgnet.com/1948-5182/full/v9/i4/217.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i4.217